Olema Pharmaceuticals (NASDAQ:OLMA) Sees Unusually-High Trading Volume

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) shares saw unusually-strong trading volume on Thursday . Approximately 20,624 shares changed hands during trading, a decline of 87% from the previous session’s volume of 164,634 shares.The stock last traded at $24.93 and had previously closed at $26.25.

A number of research analysts have weighed in on the stock. Lifesci Capital reaffirmed an “outperform” rating on shares of Olema Pharmaceuticals in a research note on Monday, June 21st. Zacks Investment Research raised shares of Olema Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, July 15th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Olema Pharmaceuticals has an average rating of “Buy” and a consensus price target of $60.67.

The company has a fifty day moving average price of $26.74.

Olema Pharmaceuticals (NASDAQ:OLMA) last posted its earnings results on Tuesday, May 11th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.11). On average, analysts anticipate that Olema Pharmaceuticals, Inc. will post -1.71 EPS for the current year.

In other Olema Pharmaceuticals news, CTO Cyrus Harmon sold 4,123 shares of Olema Pharmaceuticals stock in a transaction dated Tuesday, July 20th. The stock was sold at an average price of $25.63, for a total transaction of $105,672.49. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Kinney Horn sold 5,251 shares of Olema Pharmaceuticals stock in a transaction dated Thursday, June 10th. The shares were sold at an average price of $29.72, for a total value of $156,059.72. Following the transaction, the insider now directly owns 7,041 shares of the company’s stock, valued at approximately $209,258.52. The disclosure for this sale can be found here. Insiders sold 84,388 shares of company stock valued at $2,093,513 in the last ninety days. 23.60% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently modified their holdings of OLMA. Royal Bank of Canada bought a new stake in shares of Olema Pharmaceuticals during the 1st quarter valued at about $37,000. Strs Ohio bought a new stake in Olema Pharmaceuticals in the 1st quarter worth approximately $96,000. New York State Common Retirement Fund bought a new stake in Olema Pharmaceuticals in the 1st quarter worth approximately $199,000. American Financial Group Inc. bought a new stake in Olema Pharmaceuticals in the 1st quarter worth approximately $212,000. Finally, Ensign Peak Advisors Inc bought a new stake in Olema Pharmaceuticals in the 1st quarter worth approximately $219,000. Hedge funds and other institutional investors own 87.72% of the company’s stock.

Olema Pharmaceuticals Company Profile (NASDAQ:OLMA)

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.

Recommended Story: Real Estate Investment Trust (REIT) ETF

Receive News & Ratings for Olema Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olema Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.